Start Date
July 31, 2008
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
erlotinib hydrochloride
Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
temozolomide
Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
stereotactic radiosurgery
Stereotactic radiosurgery will be performed prior to chemotherapy.
Collaborators (2)
National Cancer Institute (NCI)
NIH
Schering-Plough
INDUSTRY
Genentech, Inc.
INDUSTRY
University of Medicine and Dentistry of New Jersey
OTHER